BCL2 and B-cell chronic lymphocytic leukemia: Primary resistance to cBTKi and BCL2 inhibitors is extremely rare clinically and resistance variants in BTK and BCL2 have not been observed in CLL specimens prior to the relevant drug exposure [90].